AU · rank #14 · 2026-07-21
CLPT
NASDAQ · $495M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.026 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 0 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.163 |
| Analyst upside Consensus target $28.33 | +88.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +27.68% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 5.00 |
| Gross margin TTM | +62.3% |
| 52w high | $30.10 |
| Market cap (USD) | $495M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
ClearPoint Neuro (CLPT) makes image-guided neurosurgical navigation, drug-delivery, and laser ablation tools for brain and spine procedures, with growing exposure to cell and gene therapy enabling workflows.
Rationale
The screen is supported by extreme sell-side upside (88% to target), a unanimous bearish-to-neutral coverage profile that still embeds a 5.0 average rating, improving momentum, and rising gross margin despite a small-cap base.
Material risks
- 1CLPT still lacks durable revenue visibility and operates without a backlog/contracted pull-through moat, so adoption can stall if customers shift to in-house solutions or competing platforms.
- 2The company remains loss-making and just posted an EPS miss, so any slowdown in navigation or disposable adoption could force capital raises before the revenue ramp fully offsets burn.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.